The in cis compound EGFR mutations in Chinese advanced non-small cell lung cancer patients

• Published in: Cancer biology & therapy 2019-08, Vol.20 (8), p.1097-1104
• Main Authors: Li, Min, Zhou, Cheng-Zhi, Yang, Jin-Ji, Lu, Shun, Zheng, Di, Hu, Jie, Zeng, Hui, Lu, You, Lu, Kai-Hua, Li, Shu-Ang, Mao, Xin-Ru, Han-Zhang, Han, Lizaso, Analyn, Ye, Jun-Yi, Hu, Cheng-Ping
• Format: Article
• Language: English
• Subjects: Chinese; compound mutations; EGFR; In cis; non-small cell lung cancer; Research Paper
• ISSN: 1538-4047; 1555-8576
• DOI: 10.1080/15384047.2019.1595280

Literatures regarding the prevalence and clinical significance of compound EGFR mutations are limited. Until now, none of retrospective or prospective research has focused on in cis compound EGFR mutations except case reports. In this study, we screened a cohort of 3,000 treatment-naïve Chinese advanced NSCLC patients using capture-based ultra-deep targeted sequencing to evaluate the prevalence of EGFR in cis compound mutations and the efficacy of EGFR-TKI in this population. Of the 3,000 patients screened, 1,266 (42.2%) had EGFR mutation; among them, 15 patients (1.2%) harboring in cis compound EGFR mutations, with 10 patients carrying EGFR L858R in combination with a rare mutation and five patients carrying two rare EGFR mutations. No patient with EGFR 19del was observed. Interestingly, no in trans configuration was identified in this cohort. All of the patients harboring in cis compound EGFR mutations were non-smokers, histologically diagnosed with adenocarcinoma and received first-generation EGFR-TKI. Furthermore, our data also revealed that patients with in cis compound EGFR mutations exhibit comparable PFS to first generation EGFR-TKI comparing to patients with single activating EGFR mutation. This observation was further supported by in silico molecular modeling analyses which demonstrated in cis compound mutations do not alter the ATP-binding pocket of EGFR, thus having no effect on the interaction between gefitinib and EGFR.